Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Cyprus

European Research Council grant · Running

BactoNanoVax Revolutionizing mRNA Cancer Vaccines with Nanosized Bacterial Outer Membrane Vesicles

Coordinator
University of Cyprus, Cyprus
Runs
1 November 2026 to 31 October 2031
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101300371

What the project is doing

In the project's own words, from its summary on CORDIS.

mRNA vaccines have garnered significant attention for their transformative potential in cancer immunotherapy. Despite their promise in eliciting immune responses against tumor antigens, mRNA vaccines still face several challenges, primarily related to limitations of lipid nanoparticle (LNP)-based formulations and the immunosuppressive role of the tumor microenvironment. Another immunotherapy modality, immune checkpoint inhibitors (ICIs), which block inhibitory signals that suppress T cell activation, can enhance the effectiveness of mRNA vaccines.

However, ICIs have their own limitations, including low response rates and significant immune-related adverse events. BactoNanoVax aims to revolutionize cancer immunotherapy by combining these two cutting-edge immunotherapy modalities co-delivered through outer membrane vesicles (OMVs) derived from engineered bacteria. I hypothesize that by leveraging the unique capabilities of OMVs over LNPs as drug delivery systems (i.e., superior stability, immunogenicity, cost of production), I will enhance the efficacy of mRNA vaccines and ICIs, drastically overcoming the immunosuppressive tumor microenvironment and leading to enhanced therapeutic outcomes in immunotherapy-resistant tumors.

BactoNanoVax will also integrate a tumor microenvironment reprogramming strategy, repurposing the clinically approved anti-histamine ketotifen to optimize OMVs intratumoral delivery and immune cell infiltration. This highly interdisciplinary research combines expertise in tumor biology, synthetic biology, microbiology, immunology and drug delivery, and it represents a pioneering approach in cancer immunotherapy. The development of OMV-based immunotherapy will revolutionize the field of precision oncology by providing a novel, highly effective therapeutic product that reduces the risk of adverse events, eliminates the need for additional immune adjuvants, and is cost-effective in production and transportation.

Topics

Who is involved

OrganisationCityCountryRole
University of CyprusNicosiaCyprusCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI